Cresco Labs (OTCMKTS:CRLBF - Get Free Report) was downgraded by equities researchers at Atb Cap Markets from a "strong-buy" rating to a "hold" rating in a research report issued on Monday,Zacks.com reports.
Several other research analysts have also issued reports on the stock. Cormark lowered shares of Cresco Labs from a "moderate buy" rating to a "hold" rating in a research report on Monday, November 11th. Roth Capital raised shares of Cresco Labs to a "strong-buy" rating in a research report on Sunday, November 10th. Finally, Needham & Company LLC restated a "hold" rating on shares of Cresco Labs in a report on Monday, August 12th. Four research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $2.50.
Read Our Latest Research Report on CRLBF
Cresco Labs Stock Down 3.3 %
OTCMKTS:CRLBF traded down $0.04 during mid-day trading on Monday, reaching $1.04. The stock had a trading volume of 687,161 shares, compared to its average volume of 750,139. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.97 and a quick ratio of 1.39. The stock's 50 day simple moving average is $1.40 and its two-hundred day simple moving average is $1.58. Cresco Labs has a 1-year low of $1.02 and a 1-year high of $2.65. The company has a market capitalization of $507.67 million, a price-to-earnings ratio of -5.38 and a beta of 1.73.
About Cresco Labs
(
Get Free Report)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Recommended Stories
Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.